beta-carotene and Porphyria-Cutanea-Tarda

beta-carotene has been researched along with Porphyria-Cutanea-Tarda* in 2 studies

Reviews

1 review(s) available for beta-carotene and Porphyria-Cutanea-Tarda

ArticleYear
Management of acute and cutaneous porphyrias.
    International journal of clinical practice, 2002, Volume: 56, Issue:4

    The porphyrias comprise a group of disorders of the haem biosynthesis pathway that can present with acute neurovisceral symptoms, skin lesions or both. Acute porphyrias present with severe abdominal pain, confusion and seizures which may be life-threatening. Specific treatment with haem preparations should be instituted as soon as possible following confirmation of increased excretion of porphobilinogen in the urine. Supportive treatment includes opiate analgesia, monitoring for and treating complications such as hypertension and hyponatraemia. Follow-up should include counselling on lifestyle modification involving avoidance of alcohol, smoking and known porphyrogenic drugs and diet. Identification and counselling of at risk relatives is essential. The cutaneous porphyrias result from porphyrin-induced photosensitivity and can present with either acute photosensitivity or skin fragility and blisters. All cutaneous porphyrias can be alleviated by avoidance of sunlight. Treatment of erythropoietic protoporphyria involves administering large doses of beta-carotene, which may improve tolerance to sunlight. Porphyria cutanea tarda can be effectively treated by phlebotomy or low dose chloroquine. Congenital erythropoietic porphyria is a rare, early onset, severe, photomutilating condition for which bone marrow transplantation has been shown to be successful.

    Topics: Arginine; beta Carotene; Chloroquine; Estrogens; Ethanol; Heme; Humans; Phlebotomy; Porphyria Cutanea Tarda; Porphyria, Acute Intermittent; Porphyrias; Sunlight

2002

Other Studies

1 other study(ies) available for beta-carotene and Porphyria-Cutanea-Tarda

ArticleYear
Liposoluble vitamins and naturally occurring carotenoids in porphyria cutanea tarda.
    European journal of clinical investigation, 1995, Volume: 25, Issue:7

    The authors consider two groups of patients with overt sporadic porphyria cutanea tarda (PCT) from different continents, with the aim of evaluating the possible impairment of the liposoluble antioxidative system, given the possible synergic effect of porphyrins and iron in promoting oxidative cellular damage. Twenty-three Italian outpatients with overt sporadic PCT and 11 outpatients with PCT from Buenos Aires (Argentina) were matched with 60 patients with liver cirrhosis and 52 healthy Italian controls. Serum levels of alpha- and beta-carotene, cryptoxanthin, zeaxanthin, lutein, lycopene, retinol and alpha-tocopherol were detected by a high-performance liquid chromatographic technique devised in our laboratory, which afforded an accurate and simultaneous resolution of all these compounds. The results point to a significant reduction in plasma levels of alpha- and beta-carotene in both the PCT populations with respect not only to controls, but also to the cirrhotic population, which had more severe liver damage. Moreover, other carotenoids with proven antioxidative properties, like cryptoxanthin and lycopene, are greatly reduced in our PCT populations. This confirms the suggested synergic effect of iron and porphyrins in the oxidative intracellular damage with consequent depletion of antioxidative liposoluble molecules.

    Topics: Alkaline Phosphatase; Analysis of Variance; Antioxidants; Argentina; beta Carotene; Bilirubin; Carotenoids; Case-Control Studies; Cholesterol; Creatinine; Cryptoxanthins; Female; Humans; Italy; Liver Cirrhosis; Lutein; Lycopene; Male; Middle Aged; Porphyria Cutanea Tarda; Prothrombin; Reference Values; Serum Albumin; Vitamin A; Vitamins; Xanthophylls; Zeaxanthins

1995